Answers are grounded in this paper and cite their sources.
Literature review reveals recurring IDH1 and IDH2 mutations in gliomas and leukemias, highlighting neomorphic D-2-hydroxyglutarate production as a therapeutic target.
Dysregulation of metabolism is a common phenomenon in cancer cells. The NADP+-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) function at a crossroads of cellular metabolism in lipid synthesis, cellular defense against oxidative stress, oxidative respiration, and oxygen-sensing signal transduction. We review the normal functions of the encoded enzymes, frequent mutations of <it>IDH1</it> and <it>IDH2</it> recently found in human cancers, and possible roles for the mutated enzymes in human disease. <it>IDH1</it> and <it>IDH2</it> mutations occur frequently in some types of World Health Organization grades 2–4 gliomas and in acute myeloid leukemias with normal karyotype. <it>IDH1</it> and <it>IDH2</it> mutations are remarkably specific to codons that encode conserved functionally important arginines in the active site of each enzyme. To date, all <it>IDH1</it> mutations have been identified at the Arg132 codon. Mutations in <it>IDH2</it> have been identified at the Arg140 codon, as well as at Arg172, which is aligned with <it>IDH1</it> Arg132. <it>IDH1</it> and <it>IDH2</it> mutations are usually heterozygous in cancer, and they appear to confer a neomorphic enzyme activity for the enzymes to catalyze the production of d-2-hydroxyglutarate. Study of alterations in these metabolic enzymes may provide insights into the metabolism of cancer cells and uncover novel avenues for development of anticancer therapeutics.
No takes yet. Share an insight, caveat, or question.
Reitman et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: